164 related articles for article (PubMed ID: 34845442)
1. Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction.
Rouhani SJ; Trujillo JA; Pyzer AR; Yu J; Fessler J; Cabanov A; Higgs EF; Cron KR; Zha Y; Lu Y; Bloodworth JC; Abasiyanik MF; Okrah S; Flood BA; Hatogai K; Leung MY; Pezeshk A; Kozloff L; Reschke R; Strohbehn GW; Chervin CS; Kumar M; Schrantz S; Madariaga ML; Beavis KG; Yeo KJ; Sweis RF; Segal J; Tay S; Izumchenko E; Mueller J; Chen LS; Gajewski TF
Res Sq; 2021 Nov; ():. PubMed ID: 34845442
[TBL] [Abstract][Full Text] [Related]
2. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
3. Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease.
Mudd PA; Crawford JC; Turner JS; Souquette A; Reynolds D; Bender D; Bosanquet JP; Anand NJ; Striker DA; Martin RS; Boon ACM; House SL; Remy KE; Hotchkiss RS; Presti RM; OHalloran JA; Powderly WG; Thomas PG; Ellebedy AH
medRxiv; 2020 May; ():. PubMed ID: 32511543
[TBL] [Abstract][Full Text] [Related]
4. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary immune cells and inflammatory cytokine dysregulation are associated with mortality of IL-1R1
Guo L; Wang YC; Mei JJ; Ning RT; Wang JJ; Li JQ; Wang X; Zheng HW; Fan HT; Liu LD
Zool Res; 2017 May; 38(3):146-154. PubMed ID: 28585438
[TBL] [Abstract][Full Text] [Related]
6. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
9. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
11. The Landscape of Expressed Chimeric Transcripts in the Blood of Severe COVID-19 Infected Patients.
Mukherjee SB; Detroja R; Mukherjee S; Frenkel-Morgenstern M
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851647
[TBL] [Abstract][Full Text] [Related]
12. mRNA-lncRNA Co-Expression Network Analysis Reveals the Role of lncRNAs in Immune Dysfunction during Severe SARS-CoV-2 Infection.
Mukherjee S; Banerjee B; Karasik D; Frenkel-Morgenstern M
Viruses; 2021 Mar; 13(3):. PubMed ID: 33802569
[TBL] [Abstract][Full Text] [Related]
13. Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.
Bosteels C; Maes B; Van Damme K; De Leeuw E; Declercq J; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):491. PubMed ID: 32503663
[TBL] [Abstract][Full Text] [Related]
14. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol.
Pinto RA; Arredondo SM; Bono MR; Gaggero AA; Díaz PV
Pediatrics; 2006 May; 117(5):e878-86. PubMed ID: 16618789
[TBL] [Abstract][Full Text] [Related]
15. Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial.
Declercq J; Bosteels C; Van Damme K; De Leeuw E; Maes B; Vandecauter A; Vermeersch S; Delporte A; Demeyere B; Vuylsteke M; Lalla M; Smart T; Detalle L; Bouw R; Streffer J; Degeeter T; Vergotte M; Guisez T; Van Braeckel E; Van Der Straeten C; Lambrecht BN
Trials; 2020 Nov; 21(1):934. PubMed ID: 33213529
[TBL] [Abstract][Full Text] [Related]
16. IL-13 is a driver of COVID-19 severity.
Donlan AN; Sutherland TE; Marie C; Preissner S; Bradley BT; Carpenter RM; Sturek JM; Ma JZ; Moreau GB; Donowitz JR; Buck GA; Serrano MG; Burgess SL; Abhyankar MM; Mura C; Bourne PE; Preissner R; Young MK; Lyons GR; Loomba JJ; Ratcliffe SJ; Poulter MD; Mathers AJ; Day AJ; Mann BJ; Allen JE; Petri WA
JCI Insight; 2021 Aug; 6(15):. PubMed ID: 34185704
[TBL] [Abstract][Full Text] [Related]
17. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
18. NEUROPROTECTIVE AND ANTIOXIDANT POTENTIAL OF MONTELUKAST-ACETYLCYSTEINE COMBINATION THERAPY FOR BRAIN PROTECTION IN PATIENTS WITH COVID-19 INDUCED PNEUMONIA.
Samsonia M; Kandelaki M; Baratashvili N; Gvaramia L
Georgian Med News; 2023 Feb; (335):111-118. PubMed ID: 37042600
[TBL] [Abstract][Full Text] [Related]
19. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
[TBL] [Abstract][Full Text] [Related]
20. IL-13 is a driver of COVID-19 severity.
Donlan AN; Sutherland TE; Marie C; Preissner S; Bradley BT; Carpenter RM; Sturek JM; Ma JZ; Moreau GB; Donowitz JR; Buck GA; Serrano MG; Burgess SL; Abhyankar MM; Mura C; Bourne PE; Preissner R; Young MK; Lyons GR; Loomba JJ; Ratcliffe SJ; Poulter MD; Mathers AJ; Day A; Mann BJ; Allen JE; Petri WA
medRxiv; 2021 Mar; ():. PubMed ID: 33688686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
